

Karyopharm Therapeutics (KPTI : US\$35.75)

Karyopharm Therapeutics continues uptrend, now soars 55% and in top 4% of the market

Karyopharm Therapeutics Inc, has now soared US\$12.74 (or 55.4%) year to date in 2014 to close at US\$35.75. This gain means the stock is among the top 4% of NASDAQ-listed stocks in 2014. The volume YTD has been 0.9 times average trading of 181,543 shares. Compared with the NASDAQ-100 Index which has risen 6.0% YTD, this represents a relative price increase of 49.4%.

Introduction

We are currently bullish on this stock in the short-term based on technical indicators, but are more bearish in the long-term based on fundamental metrics

What makes us most bullish on the stock is the following:

- Its Moving Average Convergence Divergence indicators are rising, with its 12-day EMA higher than its 26-day EMA.
- It is beating 97% of the market the past 6 months.

Stock Summary

Sector	Healthcare-Products
ISIN	US48576U1060
Relative Strength (3 mo)	29

MCap: A Historical Perspective

Share Price (USD)	Market Cap (\$)
-------------------	-----------------


Analysis

Bullish Signals

- In the last 9 trading sessions there has been a net rise of 36.07%; the stock has advanced seven times and the biggest one day rise was 46.1% on Jun 13.
- In the NASDAQ market of 2,339 stocks traded today, the stock has a 6-month relative strength of 97 which means it is beating 97% of the market.
- A price rise combined with a high relative strength is a bullish signal.
- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 27.09 minus the 26-day EMA of 26.79 is positive suggesting a bullish signal. Both the 12-day EMA as well as the 26-day EMA are rising, another bullish signal.
- The stock traded at a three-month high of US\$36.21 today.

Other Bullish Signals:

% Growth Y.O.Y, Revenue & Net Profit



Bullish Indicators and Rank in Market:

Description	Value	Rank In Market
Price Change %	46.1	In Top 1%
%Prem To Vol Wtd Price	27.5	In Top 2%
Relative Strength (6M)	97	In Top 4%

Bearish Signals

- The price is at a premium of 27.5% to the 1-month volume weighted average price of US\$28.04. In the past year the premium has been greater than 27.5% just nine times, suggesting a topish level and cautious buying at the current price.
- The price has risen above the upper Bollinger band of US\$31.50; the stock is also overbought according to the Williams % R indicator of -3.8.

Other Bearish Signals:

Bearish Indicators and Rank in Market:

Description	Value	Rank In Market
Price/MAP50	0.81	In Bottom Quartile
Annual Revenue	US\$387,000	In Bottom 1%
Volatility %	48.4	In Bottom 1%

Note

Neutral Indicators and Rank in Market:

Description	Value	Rank In Market
Turnover in Quarter	US\$399.6 million	In 2nd Quartile

Insider Trades




Trailing 3 months

Turnover	US\$399.6 million
Volume	13,120,286
Volume Index (1 is avg)	1.1

Analysis (continued)


YTD Comparison Stock Sector Index




Price Volume Trend: Trailing Quarter



Weekly Price Volume Dynamics (Last 12 Weeks)



Stock v Index (Trailing Year)



Peer Group Analysis

[Sector sorting](#)

Name	Last Price	Relative strength (6-months)	MCap (Millions)	PV \$1000 (1 yr)	Revenue (Millions)	Net Profit (Millions)	Total Assets (Millions)
Agios Pharmaceuticals	47.35	99	1,606	-	26	-44	201
Relypsa	23.41	27	792	-	-	-74	106
Oxford Immunotec Global	17.16	38	282	-	39	-9	93
Nanostring Technologies	15.0	29	271	-	31	-34	64
Conatus Pharmaceuticals	7.84	87	122	-	-	-5	57
Karyopharm Therapeutics	35.75	97	-	-	0	-34	158

Recent Analyst Recommendations

Date	Brokerage	Action	Past Rating	Current Rating	Prev Target	Price Target
20-Mar-2014	RBC Capital	Lower Price Target	-	-	-	-

Reported Buying Selling by Insiders

Insider	Date	Transaction Type	No. of Shares	Price, US\$	Value, US\$
Pakianathan Deepika	May 23, 2014	Bought	1,769	26.45	46,790
Pakianathan Deepika	May 22, 2014	Bought	20,000	26.09	521,800
Pakianathan Deepika	May 21, 2014	Bought	92,650	26.19	2,426,504
Brannelly Paul	May 15, 2014	Bought	700	25.95	18,165
Brannelly Paul	May 14, 2014	Bought	800	26.93	21,544
Brannelly Paul	May 13, 2014	Bought	1,000	28.06	28,060
Primiano Christopher Brett	May 13, 2014	Bought	1,000	26.75	26,750

Company Overview

Activities

Karyopharm Therapeutics, Inc. provides biopharmaceutical products and services. The Company develops and discovers drugs for the treatment of cancer, inflammation, and diseases related to cell proliferation through activity modulation of critical pathways. Karyopharm Therapeutics serves the healthcare industry throughout the United States.

Further details can be found at www.karyopharm.com.

Regulatory Announcements

To view Recent Company Headlines, [click here](#)

June 09: Karyopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) in Patients with Hormone Refractory Prostate Cancer (SHIP Study)

May 30: Karyopharm to Webcast Investor & Analyst Briefing on Monday, June 2, 2014

May 23: Karyopharm Therapeutics insider buys

May 23: Karyopharm Therapeutics insider buys; shares at a six-day low

May 23: Karyopharm Therapeutics insider buys

May 07: Karyopharm Therapeutics Reports First Quarter Financial Results for 2014

April 22: Karyopharm Announces Five Clinical Data Presentations at ASCO 2014

To view 8-K other news for Karyopharm-Therapeutics, [click here](#)

April 17: Karyopharm Therapeutics: Changes in Registrant's Certifying Accountant

April 01: Karyopharm Therapeutics: Entry into a Material Definitive Agreement

March 05: Karyopharm Therapeutics: Results of Operations and Financial Condition

Issued Capital

It is NASDAQ's 7th largest Healthcare-Products company by total revenue.

Board and Management

Michael G. Kauffman
CEO & Director

Sharon Shacham
President & Director

Mansoor Raza Mirza
Director

Kenneth E. Weg
Director

Pakianathan Deepika
Director

Dr. Deepa R. Pakianathan, Ph.D., is Director at Karyopharm Therapeutics, Inc. She joined Delphi Ventures in 2001 and leads the firm's biotechnology investment activities. She served on the boards of Salmedix (a.b. Cephalon in 2005), Ilypsa (a.b. Amgen in 2007), Proteolix (a.b. ONXX in 2009) and led Delphi's investment in Seattle Genetics (Nasdaq: SGEN). She currently serves on the boards of Alexa Pharmaceuticals (Nasdaq: ALXA), Alder, Calithera, Karyopharm, Oncomed, NeurAxon, and PTC Therapeutics. Prior to joining Delphi, she was a Vice President in the healthcare group at JP Morgan. From 1997 to 1998, she was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997, where she evaluated chemokines and chemokine receptors as targets for therapeutic intervention. She is Vice-chair of the Board of Trustees of the San Francisco Conservatory of Music.

Deepa R. Pakianathan
Director

Barry E. Greene
Director

Primiano Christopher Brett
Company Secretary &
Vice President

Financial Results (Quarterly)

31 March, 2014

INCOME STATEMENT

Currency in Thousand of USD	2014-03-31	2013-03-31	Change %
Contract and grant revenue	171	233	Down 26.6
Operating expenses:			
Research and development	10,979	4,965	Up 121.1
General and administrative	2,904	879	Up 230.4
Total operating expenses	13,883	5,844	Up 137.6
Loss from operations	-13,712	-5,611	Deterioration 144.4
Interest income (expense), net	18		
Net loss	-13,694	-5,611	Deterioration 144.1
Net loss per share applicable to common stockholders-basic and diluted	-46.0c	-252.0c	Reduced 81.7
Weighted-average number of common shares outstanding used in net loss per share applicable to common stockholders-basic and diluted	29,606,683	2,225,596	Up 1,230.3

BALANCE SHEET

Currency in Thousand of USD	2014-03-31	2013-12-31	Change %
Assets			
Current assets:			
Cash and cash equivalents	144,893	155,974	Down 7.1
Prepaid expenses and other current assets	2,673	1,982	Up 34.9
Total current assets	147,566	157,956	Down 6.6
Property and equipment, net	322	240	Up 34.2
Other assets	997	30	Up 3,223.3
Restricted cash	400		
Total assets	149,285	158,226	Down 5.7
Liabilities and stockholders' equity			
Current liabilities:			
Accounts payable	3,273	1,740	Up 88.1
Accrued expenses	1,550	1,168	Up 32.7
Deferred revenue	57	79	Down 27.8
Other short-term liabilities	135	305	Down 55.7
Total current liabilities	5,015	3,292	Up 52.3
Other long-term liabilities	170		
Stockholders' equity			

Financial Results (Quarterly) (continued)

31 March, 2014

Convertible preferred stock, 0.0001 par value; 5,000,000 shares authorized; none issued and outstanding

Common stock, 0.0001 par value; 100,000,000 shares authorized; 3 29,618,879 and 29,587,258 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively

3

Steady

Additional paid-in capital

220,360

217,500

Up 1.3

Deficit accumulated during the development stage

-76,263

-62,569

Deterioration 21.9

Total stockholders' equity

144,100

154,934

Down 7.0

Total liabilities and stockholders' equity

149,285

158,226

Down 5.7

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

BuySellSignals publishes equity research reports on each stock, sector and index daily to capture the latest market movements and sentiments. BuySellSignals eschews "hot tip" or headline investing in favour of high-quality, ultra-current, targeted technical and fundamental information including specific bullish and bearish signals for each stock. Insights that will guide you to the investments that are hard to find in today's hyperactive mainstream markets.

For further details on definitions and quotations from investing legends, [Click here](#)

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756) and News Bites Pty Ltd, who provide round the clock data on every Australian stock and sector. Neither BuySellSignals nor News Bites are brokers, and neither have an executing, corporate advisory or investment banking function. BuySellSignals and News Bites Pty Ltd, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.
